GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (FRA:DMP) » Definitions » Equity-to-Asset

Dermapharm Holding SE (FRA:DMP) Equity-to-Asset : 0.25 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Dermapharm Holding SE's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €552 Mil. Dermapharm Holding SE's Total Assets for the quarter that ended in Jun. 2024 was €2,207 Mil. Therefore, Dermapharm Holding SE's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.25.

The historical rank and industry rank for Dermapharm Holding SE's Equity-to-Asset or its related term are showing as below:

FRA:DMP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09   Med: 0.27   Max: 0.38
Current: 0.25

During the past 11 years, the highest Equity to Asset Ratio of Dermapharm Holding SE was 0.38. The lowest was 0.09. And the median was 0.27.

FRA:DMP's Equity-to-Asset is ranked worse than
83.73% of 1039 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs FRA:DMP: 0.25

Dermapharm Holding SE Equity-to-Asset Historical Data

The historical data trend for Dermapharm Holding SE's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Equity-to-Asset Chart

Dermapharm Holding SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.26 0.35 0.38 0.25

Dermapharm Holding SE Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.25 0.25 0.27 0.25

Competitive Comparison of Dermapharm Holding SE's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Equity-to-Asset falls into.



Dermapharm Holding SE Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Dermapharm Holding SE's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=539.207/2160.673
=0.25

Dermapharm Holding SE's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=551.556/2207.102
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (FRA:DMP) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Dermapharm Holding SE Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts, and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing, and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals, and cosmetics products. Parallel import brands business operates under the AxiCorp brand.
Executives
Dr. Hans-georg Feldmeier Board of Directors

Dermapharm Holding SE Headlines

No Headlines